Physician

Atul T. Roy, M.D.

According to 2025 Medicare claims, Atul Roy, M.D. (NPI: 1467496505) practices nephrology in the Merced, CA market, with the plurality of this provider's patient population coming from Merced, CA. This provider's primary affiliated billing organization is THE NEPHROLOGY GROUP, INC. (NPI: 1205906229; TIN: 770383758) and primary practice location at 95348-9408. Roy is affiliated with the Aledade 45 CA CHC MSSP Enhanced (ACO ID: A4542), participating under the MSSP model.

Roy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 733 traditional Medicare patients, billed 6,828 HCPCS/CPT codes, and received $403,672 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,637 prescription claims across 450 beneficiaries totaling $1,567,061 in drug costs, led by Xphozah (Tenapanor Hcl). DME data shows 62 claims. Open Payments data shows 15 records totaling $369. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,579 to $8,612.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	990	62,876	$652,021
2016	915	43,826	$577,616
2017	928	38,159	$601,620
2018	901	32,636	$643,149
2019	923	31,212	$589,581
2020	787	25,705	$491,315
2021	716	8,373	$467,032
2022	793	7,203	$509,507
2023	802	7,695	$494,599
2024	733	6,828	$403,672

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	340	4,166	$857,904
2016	328	3,639	$922,225
2017	343	3,431	$931,771
2018	366	3,563	$637,651
2019	391	3,262	$591,364
2020	395	3,349	$631,067
2021	413	3,415	$582,917
2022	368	2,462	$592,636
2023	403	2,504	$952,956
2024	450	2,637	$1,567,061

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	235	$7,355
2016	16	347	$12,737
2017	N/R	303	$12,004
2018	N/R	172	$6,213
2019	N/R	206	$5,724
2020	N/R	221	$6,711
2021	N/R	186	$10,958
2022	N/R	103	$7,352
2023	N/R	95	$8,674
2024	N/R	62	$8,930

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	289	469	$58
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	275	374	$53
80053	Blood test, comprehensive group of blood chemicals	226	411	$10
36415	Insertion of needle into vein for collection of blood sample	228	422	$9
84100	Phosphate level	226	412	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	200	6,840	$602,106
Jardiance	Empagliflozin	185	13,874	$256,791
Farxiga	Dapagliflozin Propanediol	180	11,490	$207,052
Trulicity	Dulaglutide	44	2,412	$77,374
Kerendia	Finerenone	51	3,450	$72,557

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	23	$8,369
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	16	$241
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$207
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$112

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$369	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Atul T. Roy, M.D.?

Tedicare shows public-source Medicare data for Atul T. Roy, M.D. (NPI 1467496505), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Atul T. Roy, M.D. have ACO affiliation data?

Atul T. Roy, M.D. is shown with ACO affiliation data for Aledade 45 CA CHC MSSP Enhanced (MSSP, ACO ID A4542).

What billing organization is linked to Atul T. Roy, M.D.?

Atul T. Roy, M.D. is linked to THE NEPHROLOGY GROUP, INC. (billing NPI 1205906229) in the available physician profile data.

Does Atul T. Roy, M.D. have Open Payments data?

Atul T. Roy, M.D. has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.